Linked Data API

Show Search Form

Search Results

100411
registered interest false more like this
date less than 2014-10-22more like thismore than 2014-10-22
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Cystic Fibrosis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps the Government is taking to support research into new treatments for people with cystic fibrosis. more like this
tabling member constituency Barnsley Central more like this
tabling member printed
Dan Jarvis more like this
uin 211584 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-27more like thismore than 2014-10-27
answer text <p>The National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre manages the Efficacy and Mechanism Evaluation programme. With funding from the Medical Research Council, this programme is currently supporting a £3.3 million trial of repeated application of gene therapy in patients with cystic fibrosis. The report of this trial is expected to be published in August 2015.</p><p> </p><p><strong> </strong></p><p> </p><p>A range of commercial and researcher-led cystic fibrosis treatment trials and studies are hosted by NIHR research infrastructure including the NIHR Clinical Research Network, NIHR biomedical research centres and units, and NIHR clinical research facilities for experimental medicine.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
remove maximum value filtermore like thismore than 2014-10-27T16:52:12.8962611Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
4243
label Biography information for Dan Jarvis more like this
99859
registered interest false more like this
date less than 2014-10-20more like thismore than 2014-10-20
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Prescription Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, if his Department will commission a review of the innovation, evaluation and adoption of new medicines in the NHS; and if he will make a statement. more like this
tabling member constituency Scunthorpe more like this
tabling member printed
Nic Dakin more like this
uin 211101 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-23more like thismore than 2014-10-23
answer text <p>We are committed to ensuring National Health Service patients have access to effective medicines on terms that represent value to the NHS and taxpayers and that patients, are supported to get the best outcomes from their medicines.</p><p> </p><p> </p><p> </p><p>The Department, in collaboration with NHS England, has recently commissioned an independent evaluation of Innovation Health and Wealth. Jointly led by the University of Manchester and RAND Europe, The first initial phase is now underway, the study is expected to take three years to complete.</p><p> </p><p><em> </em></p><p> </p><p>In addition, NHS England, with the Health and Social Care Information Centre publishes an innovation scorecard which represents the rate of uptake and utility of medicines in both primary and secondary care, on a regular basis. This publication sets out levels of uptake and utility for National Institute for Health and Care Excellence appraised medicines and technologies, and evidence suggests that steady growth is being achieved and the most recent information is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.hscic.gov.uk/searchcatalogue?productid=15598&amp;q=innovation+scorecard&amp;sort=Relevance&amp;size=10&amp;page=1#top" target="_blank">www.hscic.gov.uk/searchcatalogue?productid=15598&amp;q=innovation+scorecard&amp;sort=Relevance&amp;size=10&amp;page=1#top</a></p><p> </p><p><strong> </strong></p><p> </p><p>Earlier this year, NHS England also undertook an extensive consultation to ‘refresh’ the Innovation Health and Wealth policy framework and we understand that recommendations from this will be included in NHS England's five year Forward Look.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-23T16:35:13.9262134Zmore like thismore than 2014-10-23T16:35:13.9262134Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
4056
label Biography information for Nic Dakin more like this
99878
registered interest false more like this
date less than 2014-10-20more like thismore than 2014-10-20
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Hepatitis: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, how much his Department spent on medicines for hepatitis C treatment in each of the last three financial years. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Luciana Berger more like this
uin 211146 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-23more like thismore than 2014-10-23
answer text <p>Information on spend by the National Health Service in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p> </p><p>Medicines for the treatment of hepatitis C have been defined as all medicines contained within British National Formulary section 5.3.3.4 - chronic hepatitis C. In addition, peginterferon alfa, ribavirin and interferon alfa have also been included as they have been recommended in National Institute for Health and Care excellence technology appraisals for use in treating hepatitis C.</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition, it may not be possible to separate the different conditions for which a drug may have been prescribed and therefore figures may include costs from prescriptions of these drugs other than for hepatitis C.</p><p> </p><p><strong> </strong></p><p> </p><p>This is the cost of the medicines at NHS list price and not necessarily the price paid. It does not take account of discounts, dispensing costs, fees or prescription charges income.</p><p> </p><p> </p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Financial Year</p></td><td><p>Cost (£000)</p></td></tr><tr><td><p>2011-12</p></td><td><p>34,198.9</p></td></tr><tr><td><p>2012-13</p></td><td><p>52,709.2</p></td></tr><tr><td><p>2013-14</p></td><td><p>72,122.0</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-23T16:40:20.5892873Zmore like thismore than 2014-10-23T16:40:20.5892873Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
4036
label Biography information for Luciana Berger more like this
93839
registered interest false more like this
date less than 2014-10-16more like thismore than 2014-10-16
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Mental Health Services more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what National Institute for Health and Care Excellence-approved interventions are available through the NHS for the treatment of mental health conditions. more like this
tabling member constituency East Worthing and Shoreham more like this
tabling member printed
Tim Loughton more like this
uin 210896 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-21more like thismore than 2014-10-21
answer text <p>The National Institute for Health and Care Excellence (NICE) has published clinical guidelines on a range of mental health topics, such as depression, anxiety and schizophrenia. Clinical guidelines provide guidance on the treatment of patients across the care pathway and each guideline recommends a number of treatments.<br> <br> Additionally, the following technologies for the treatment of mental health and behavioural conditions are recommended by NICE technology appraisal guidance:</p><p> </p><table><tbody><tr><td><p>Appraisal Number</p></td><td><p>Year</p></td><td><p>Technology</p></td><td><p>Condition</p></td><td><p>Categorisation</p></td></tr><tr><td><p>TA59</p></td><td><p>2003</p></td><td><p>Electroconvulsive therapy</p></td><td><p>Catatonia/ prolonged or severe manic episode</p></td><td><p>Optimised<sup>1</sup></p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Atomoxetine</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Dexamfetamine</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA098</p></td><td><p>2006</p></td><td><p>Methylphenidate</p></td><td><p>Attention deficit hyperactivity disorder (ADHD)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA213</p></td><td><p>2011</p></td><td><p>Aripiprazole</p></td><td><p>Schizophrenia in people aged 15-17 years</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Donepezil</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Galantamine</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Rivastigmine</p></td><td><p>Alzheimer's disease (mild to moderate)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Memantine</p></td><td><p>Alzheimer's disease (moderate)</p></td><td><p>Optimised</p></td></tr><tr><td><p>TA217</p></td><td><p>2011</p></td><td><p>Memantine</p></td><td><p>Alzheimer's disease (severe)</p></td><td><p>Recommended</p></td></tr><tr><td><p>TA292</p></td><td><p>2013</p></td><td><p>Aripiprazole</p></td><td><p>Moderate to severe manic episodes in adolescents with bipolar disorder</p></td><td><p>Recommended</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><em>Source</em>: National Institute for Health and Care Excellence</p><p> </p><p> </p><p> </p><p><sup>1 </sup>The drug or technology is recommended for a smaller subset of patients than originally stated by the marketing authorisation.</p><p> </p><p> </p><p> </p><p>Patients have the right to drugs and treatments that have been recommended by NICE technology appraisal guidance for use in the National Health Service, where their doctor believes they are clinically appropriate.</p><p> </p><p> </p><p> </p><p>Details of all NICE’s guidance on mental health and behavioural conditions can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions" target="_blank">www.nice.org.uk/guidancemenu/conditions-and-diseases/mental-health-and-behavioural-conditions</a></p><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-21T15:12:00.8391961Zmore like thismore than 2014-10-21T15:12:00.8391961Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
114
label Biography information for Tim Loughton more like this
100022
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Patient Choice Schemes more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps he is taking to promote patient choice. more like this
tabling member constituency Stroud more like this
tabling member printed
Neil Carmichael more like this
uin 905559 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-21more like thismore than 2014-10-21
answer text <p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.</p><p> </p><p> </p><p> </p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-21T16:00:56.1397924Zmore like thismore than 2014-10-21T16:00:56.1397924Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
4104
label Biography information for Neil Carmichael more like this
93556
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Pharmaceutical Price Regulation Scheme more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what discussions (a) he or (b) officials in his Department have had on reinvesting the industry rebate payments under the current Pharmaceutical Price Regulation Scheme into (i) healthcare services and (ii) medicines expenditure. more like this
tabling member constituency Cambridge more like this
tabling member printed
Dr Julian Huppert more like this
uin 210807 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-22more like thismore than 2014-10-22
answer text <p>The Pharmaceutical Price Regulation Scheme (PPRS) as agreed with the Association of the British Pharmaceutical Industry (ABPI) does not cover the onward financial flows of payments to the National Health Service which are subject to the Government accounting and budgeting rules in the normal way. In particular there was no agreement to hypothecate PPRS payments. The Department has subsequently had a number of discussions with the ABPI and NHS England about the onward financial flows.</p><p> </p><p> </p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the mandate and as such were included within commissioner allocations. The same is expected to apply in 2015-16. This means that the effect of the deal is felt across the NHS through the general funding allocations to clinical commissioning groups.</p><p> </p><p> </p><p> </p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the ABPI are discussing how best to improve access to and optimise patient outcomes from these medicines.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-22T15:38:43.80669Zmore like thismore than 2014-10-22T15:38:43.80669Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
3931
label Biography information for Dr Julian Huppert more like this
93563
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Surgical Mesh Implants more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, if he will review his policy on polypropylene transvaginal mesh implants in response to recent court judgements in the US. more like this
tabling member constituency Newcastle upon Tyne East more like this
tabling member printed
Mr Nicholas Brown more like this
uin 210655 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-22more like thismore than 2014-10-22
answer text <p>A working group, chaired by NHS England and including patient representatives, clinical representatives, the Department and the Medicines and Healthcare Products Regulatory Agency, has been set up to understand and address the concerns which have been raised about transvaginal mesh implants.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-22T15:19:50.645981Zmore like thismore than 2014-10-22T15:19:50.645981Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
523
label Biography information for Mr Nicholas Brown more like this
93566
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Pharmaceutical Price Regulation Scheme more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what the value is of the rebate payments made by industry under the Pharmaceutical Price Regulation Scheme to date; and what proportion of that rebate has been reinvested in (i) healthcare services and (ii) medicines expenditure. more like this
tabling member constituency Cambridge more like this
tabling member printed
Dr Julian Huppert more like this
uin 210640 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-20more like thismore than 2014-10-20
answer text <p>The Department has received £74 million from members of the Pharmaceutical Price Regulation Scheme (PPRS) in respect of PPRS payments for the first quarter of the calendar year 2014 and £76 million in respect of the second quarter. The Department will publish aggregate information on sales reports and payments made under the scheme on a quarterly basis. The first two quarters PPRS payments were published in June and September 2014 respectively and can be found on the Government’s website at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information" target="_blank">https://www.gov.uk/government/publications/pprs-quarterly-net-sales-and-payment-information</a></p><p> </p><p> </p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the Mandate and as such were included within commissioner allocations.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-20T16:15:30.8911788Zmore like thismore than 2014-10-20T16:15:30.8911788Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
3931
label Biography information for Dr Julian Huppert more like this
93568
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Cancer more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what funding his Department provides for businesses and organisations conducting research into the benefits of natural products in cancer therapy and treatment. more like this
tabling member constituency Belfast North more like this
tabling member printed
Mr Nigel Dodds more like this
uin 210719 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-22more like thismore than 2014-10-22
answer text <p>The Government has funding mechanisms in place for research and development relating to cancer treatments.</p><p> </p><p> </p><p> </p><p>The Department's National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including the use of natural products in cancer treatment. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>The NIHR is investing £16 million over five years (to 2017) in 14 Experimental Cancer Medicine Centres (ECMCs) across England with joint funding from Cancer Research UK. These centres bring together laboratory and clinical patient-based research to speed up the development of innovative cancer therapies and individualise patient treatment. Researchers at the Leicester ECMC are currently looking at whether curcumin – found in turmeric – can improve drug response in patients with advanced bowel cancer.</p><p> </p><p> </p><p> </p><p>The NIHR manages the Efficacy and Mechanism Evaluation programme, which bridges the gap between preclinical studies and evidence of clinical efficacy. The aim is to secure the progress of new technologies and interventions through their early clinical trials and onto larger, later clinical trials. The programme is funded by the Medical Research Council (MRC) and the NIHR and is not currently funding any studies of the use of natural products in cancer treatment.</p><p> </p><p> </p><p> </p><p>Other sources of funding include the Biomedical Catalyst, which is a funding programme jointly operated by the MRC and Innovate UK. The programme provides responsive and effective support for the best translational life science opportunities arising. Grants are available to UK academics and small and medium enterprises seeking to move their research more quickly from discovery to commercialisation.</p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
question first answered
less than 2014-10-22T15:10:04.2140072Zmore like thismore than 2014-10-22T15:10:04.2140072Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
1388
label Biography information for Lord Dodds of Duncairn more like this
93570
registered interest false more like this
date less than 2014-10-15more like thismore than 2014-10-15
answering body
Department of Health more like this
answering dept id 17 remove filter
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Diabetes more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what the cost was of providing free prescriptions to people with diabetes in (a) England and (b) Havering in 2013-14. more like this
tabling member constituency Romford more like this
tabling member printed
Andrew Rosindell more like this
uin 210702 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-10-22more like thismore than 2014-10-22
answer text <p>Information is not available in the format requested</p><p> </p><p> </p><p> </p><p>Diabetes and Myxoedema are two of the specific conditions which entitle individuals to apply for a medical exemption certificate to provide them with exemption from prescription charges.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman more like this
grouped question UIN 210703 more like this
question first answered
less than 2014-10-22T15:33:24.5802945Zmore like thismore than 2014-10-22T15:33:24.5802945Z
answering member
4020
label Biography information for George Freeman remove filter
tabling member
1447
label Biography information for Andrew Rosindell more like this